Nasdaq and the Tel Aviv Stock Exchange-listed Compugen, a clinical-stage therapeutic discovery and development company, has appointed David Silberman as its new CFO, effective August 15, 2024. He replaces Alberto Sessa. Silberman joins Compugen…
Israel: Silberman appointed as new CFO at Compugen
…
…






